Safety of dexmedetomidine for the control of agitation in critically ill traumatic brain injury patients: a descriptive study.

Véronique BilodeauMar Saavedra-MitjansAnne Julie FrenetteLisa BurryMartin AlbertFrancis BernardDavid R Williamson

Published in: Journal of clinical pharmacy and therapeutics (2021)

Dexmedetomidine use was safe and associated with a reduction in agitation in traumatic brain injury patients in the 96 hours following its initiation.

Keyphrases

traumatic brain injury
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
acute kidney injury